#USA #Biologics #Tetrous #EnFix #Sherman Oaks

Tetrous, Inc. Successfully Closes $6.5 Million in Series A Financing

Tetrous, Inc., a promising startup based in Sherman Oaks, focused on innovative solutions for bone-to-tendon healing following orthopedic surgeries, recently announced the successful closure of its Series A financing round. This round raised an impressive total of $6,500,000, surpassing the original goal of $5,000,000 due to overwhelming interest from a diverse group of accredited investors, including strategic partners.

Investment Details

The financing, structured as a Reg D offering, attracted significant investment from Tetrous's manufacturing and distribution partners located in the USA and Australia. Moreover, the enthusiasm from existing shareholders and management further propelled the raise. Over 50% of the funds were contributed by these strategic partners, highlighting a robust belief in Tetrous's potential to revolutionize orthopedic treatments.

Addressing Critical Needs in Medicine

Investors are particularly excited about Tetrous’s mission to redefine bone-to-tendon repair. This technology is not only vital but also addresses a major unmet need in the medical field, particularly regarding the enthesis—the critical junction where tendon meets bone. Current data indicates a troubling failure rate of 13% to 94% for rotator cuff repairs, underscoring the necessity for effective solutions.

Strategic Use of Funds

The funds raised will be pivotal for expanding Tetrous's market penetration while also developing clinical data that demonstrates improved patient outcomes through the company’s proprietary technology. Plans include extending surgical applications of their patented technology, particularly to areas like hip, knee, ankle, and elbow procedures.

CEO Bradley Patt expressed enthusiasm about the financing success and the confidence shown by investors. He stated, “This funding allows us to enhance our product offerings, broaden our reach, and continue delivering exceptional value to our customers. It’s all about the enthesis.”

Simon Berry, CEO of Tetrous’s partner, Australian Biotechnologies, echoed this sentiment, noting that biologic healing represents the future of bone-tendon healing. He commended Tetrous for their impressive growth vision and their commitment to innovation in the sports medicine field.

EnFix® Product Line

One of the key components of Tetrous's innovation is the EnFix® family of allograft products, specifically engineered to improve healing at the enthesis. These products utilize 100% demineralized bone fiber (DBF), which offers both osteoinductivity and osteoconductivity, thereby optimizing biological performance while minimizing disruption to established surgical techniques.

With over 150,000 implants used in spinal applications, Tetrous is leveraging core technology originally intended for spine surgery to explore new applications within sports medicine. They hold robust intellectual property protections for their product offerings with multiple patents granted and a unique license for the demineralized bone fiber technology from TheraCell, a subsidiary of ISTO Biologics.

Conclusion

Founded in 2019, Tetrous continues to innovate in the orthopedic sector while addressing the pressing needs of bone-to-tendon healing. As they navigate their market expansion, the enhancements in technology and strategic partnerships place them in a strong position for future growth. For further information on their products like EnFix RC and EnFix TAC, you can visit their website at www.tetrous.com. Follow them on LinkedIn for updates on their exciting journey in the realm of sports medicine.